ABSTRACT NUMBER: ESOC2026A374 EFFECTIVENESS OF ABOBOTULINUMTOXINA IN STROKE SURVIVORS WITH LOWER LIMB SPASTICITY

Abstract Background and aims Up to 40% of stroke survivors will develop spasticity which may affect mobility and cause pain. We evaluated longitudinal goal attainment with repeated abobotulinumtoxinA (aboBoNT-A) injections for leg spasticity management in routine clinical practice. Methods AboLiSh was a 16-month observational study (NCT04050527) of ambulatory adults (≥18y, able to take ≥5 steps) with unilateral leg spasticity treated with aboBoNT-A per local guidelines to achieve personalised goals. Post-hoc analyses assessed cumulative goal attainment (GAS-leg) across cycles in stroke survivors with ≥1 injection and ≥1 GAS-leg assessment (n=328). Results At Cycle 1, the most popular primary goals were related to locomotion (39.6%) followed by pain/discomfort (18.6%). At Cycle 1, the median aboBoNT-A dose for the leg was 600U [range 100-1500U]. Muscle selection was consistent with foot equinus and/or varus; the most commonly injected muscles were the gastrocnemius (medial head 84%; lateral head 74%), soleus (67%), tibialis posterior (52%), flexor digitorum longus (41%), and flexor hallucis longus (22%). 64% of participants also required injections for arm spasticity; in these cases the median total body dose increased to 1362.5U. Goals were generally achieved as expected over repeated cycles. The mean [95%CI] cumulated GAS-leg T score at 16 months was 48.2 [47.5, 49.0] (median: 50). Change in cumulated GAS T scores were clinically relevant; the mean change in GAS-leg score was 9.9 [9.1, 10.7] (median: 10). Conclusions Results from this prospective, longitudinal real-world study demonstrate the sustained functional benefit of repeated cycles of aboBoNT-A for leg spasticity, as assessed by person-centered goal attainment. Conflict of interest Richard D. Zorowitz, Stephen Ashford, Jorge Jacinto and Alberto Esquenazi are part of the AboLiSh study which is sponsored by Ipsen. Mathieu Beneteau, Pascal Maisonobe, and Christian Hannes are employed by Ipsen.

Authors

Institutions

Publication Details

Journal
European Stroke Journal
Published
2026-05-01
DOI
https://doi.org/10.1093/esj/aakag023.274
Primary Topic
Botulinum Toxin and Related Neurological Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ABSTRACT NUMBER: ESOC2026A374 EFFECTIVENESS OF ABOBOTULINUMTOXINA IN STROKE SURVIVORS WITH LOWER LIMB SPASTICITY

Pascal Maisonobe, Christian Hannes, Richard Zorowitz, Jorge Jacinto et al.
European Stroke Journal
Botulinum Toxin and Related Neurological Disorders
article

ABSTRACT NUMBER: ESOC2026A374 EFFECTIVENESS OF ABOBOTULINUMTOXINA IN STROKE SURVIVORS WITH LOWER LIMB SPASTICITY

Pascal Maisonobe, Christian Hannes, Richard Zorowitz, Jorge Jacinto, Alberto Esquenazi, Stephen Ashford, Mathieu Beneteau
article en

Abstract

Abstract Background and aims Up to 40% of stroke survivors will develop spasticity which may affect mobility and cause pain. We evaluated longitudinal goal attainment with repeated abobotulinumtoxinA (aboBoNT-A) injections for leg spasticity management in routine clinical practice. Methods AboLiSh was a 16-month observational study (NCT04050527) of ambulatory adults (≥18y, able to take ≥5 steps) with unilateral leg spasticity treated with aboBoNT-A per local guidelines to achieve personalised goals. Post-hoc analyses assessed cumulative goal attainment (GAS-leg) across cycles in stroke survivors with ≥1 injection and ≥1 GAS-leg assessment (n=328). Results At Cycle 1, the most popular primary goals were related to locomotion (39.6%) followed by pain/discomfort (18.6%). At Cycle 1, the median aboBoNT-A dose for the leg was 600U [range 100-1500U]. Muscle selection was consistent with foot equinus and/or varus; the most commonly injected muscles were the gastrocnemius (medial head 84%; lateral head 74%), soleus (67%), tibialis posterior (52%), flexor digitorum longus (41%), and flexor hallucis longus (22%). 64% of participants also required injections for arm spasticity; in these cases the median total body dose increased to 1362.5U. Goals were generally achieved as expected over repeated cycles. The mean [95%CI] cumulated GAS-leg T score at 16 months was 48.2 [47.5, 49.0] (median: 50). Change in cumulated GAS T scores were clinically relevant; the mean change in GAS-leg score was 9.9 [9.1, 10.7] (median: 10). Conclusions Results from this prospective, longitudinal real-world study demonstrate the sustained functional benefit of repeated cycles of aboBoNT-A for leg spasticity, as assessed by person-centered goal attainment. Conflict of interest Richard D. Zorowitz, Stephen Ashford, Jorge Jacinto and Alberto Esquenazi are part of the AboLiSh study which is sponsored by Ipsen. Mathieu Beneteau, Pascal Maisonobe, and Christian Hannes are employed by Ipsen.

European Stroke JournalVol. 11(Supplement_1)
Ipsen (France) (FR), Georgetown University (US), Magee Rehabilitation Hospital (US), London North West Healthcare NHS Trust (GB), MedStar Georgetown University Hospital (US), Ipsen (Germany) (DE), Moss Rehabilitation Hospital (US), Centro de Medicina de Reabilitacao do Alcoitão (PT)
Openalex Percentile: Top 9%
Botulinum Toxin and Related Neurological Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.